We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Teva in Europe

Supporting Europe’s medicine supply chain

Teva is located across all major markets in Europe, operating across 28 manufacturing sites and employing over 19,000 people across its operations and commercial arm. We’re the leading generic drug company in Europe, and we also have a strong specialty medicines portfolio focused on central nervous system disorders, respiratory diseases and oncology.

Making Medicines in Europe

Addressing Europe’s Essential Medicines Exodus

The case for change in Europe

“The resilience of Teva’s operation never fails to surprise me”

Meet Romana Santar

Teva Factsheet

Pharmaceutical Manufacturing Resilience in EU

COVID-19 puts medicine supply security in Europe's spotlight

The case of Europe's disappearing medicine cabinet

NEW Teva Critical Medicines Health Check

european union flag

NEW Teva EU Elections Manifesto "We are all in for Europe's better health

Manufacturing Resilience

Policy Insights

Executive Summary - Policy Lessons from COVID-19

Position Paper -
Teva’s views on COVID-19: Policy & Advocacy Commitments

Policy lessons from COVID-19: Savanta ComRes research report for Teva Pharmaceuticals

Security of supply

Teva consumer research on manufacturing resilience

Teva Q&A on security of supply

Teva position paper on security of supply

The path towards better security of supply in Europe